ArticleFrontiers in medicine2025
Prognostic biomarkers for overall survival in patients undergoing surgery for bone metastases: a pan-cancer study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surgery of the tumors of the spine.EFORT open reviews · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prompt diagnosis and prognostic assessment of bone metastases (BMs) remain challenging with most studies and prognostic models focusing on a single primary tumor and neglect host-related biomarkers. Therefore, this pan-cancer study aimed to evaluate bone metabolism, inflammatory, and hematological biomarkers in patients undergoing surgery for BMs, identify risk factors for BM development, and create a prognostic nomogram. A prospective cohort of adult patients with histologically confirmed BMs from various cancers was enrolled between 2020 and 2023. Baseline data included demographics, tumor type, and preoperative biomarkers such as bone turnover markers (P1NP, BAP), calcium, LDH, IGFBP-3, HALP, RDW, and NLR. Outcomes were recurrence, metastasis, and overall survival (OS), analyzed with Kaplan-Meier and Cox regression. Prognostic variables were integrated into a nomogram and validated by ROC curves and calibration. Ninety-one patients underwent surgery for BM. The most frequent primary cancers were breast (28.6%), kidney (23.1%), and lung (16.5%). Significant tumor-type differences were observed in BAP (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.